Showing results (51-60 of 102) with videos related to
Sort By:
Pageof 11
Biochemical and Biophysical Research Communications|June 16, 2009
Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8Tao Lan, Mallikarjuna Reddy Putta, Daqing Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer modelsZhuo Zhang, Hui Wang, Gautam Prasad, et al.Bioconjugate Chemistry|December 22, 2009
Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activityMallikarjuna Reddy Putta, Fu-Gang Zhu, Daqing Wang, et al.Biochemical and Biophysical Research Communications|June 25, 2003
Secondary structures in CpG oligonucleotides affect immunostimulatory activityEkambar R Kandimalla, Lakshmi Bhagat, Yan-Ping Cong, et al.Journal of Medicinal Chemistry|December 24, 2008
Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9Daqing Wang, Lakshmi Bhagat, Dong Yu, et al.International Journal of Oncology|June 14, 2002
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicityHui Wang, Jie Hang, Zhenqi Shi, et al.Annals of the New York Academy of Sciences|January 6, 2006
Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640Eric C Lacasse, Ekambar R Kandimalla, Peter Winocour, et al.The Prostate|January 16, 2008
Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivoZhaomei Mu, Paul Hachem, Harvey Hensley, et al.Biochemical and Biophysical Research Communications|October 16, 2003
Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cellsYan-Ping Cong, Sam S Song, Lakshmi Bhagat, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumorsSanjay Goel, Kavita Desai, Anca Bulgaru, et al.Pageof 11